Quantum Computing

Quantum Computing Inc. rose 7.2% to $6.87 on Monday as the quantum group rebounded together, with IONQ and RGTI each up nearly 5% intraday. QUBT started pre-market at $6.39, opened at $6.56, climbed to an intraday high of $6.918 at 12:37 ET and consolidated near $6.89 after hours, on 6.96 million shares and $47.3 million of turnover. The company also said it will host its third-quarter 2026 results call on November 9. Fundamentals remain thin relative to revenue: Q2 2026 sales were $5.551 million, up roughly 90x year over year, while net loss widened to $11.753 million, a -211.7% net margin and EPS of -$0.0523. At $6.87 the stock still sits below its MA20 of $7.14 and MA60 of $8.06, is down 37.6% year to date, 59.1% below the 52-week high of $16.79 and just 13.0% above the 52-week low of $6.08 set on October 15, with a 0.98 price-to-book. A 3.47% turnover rate suggests active positioning, though follow-through likely depends on sector flows rather than earnings.

Quantum names rallied with the AI trade, lifting QUBT about 5.1% to $6.83 in Wednesday's US regular session: pre-market stayed inside $6.60-$6.72, the stock dipped to $6.555 at 10:16 ET and ran to $6.855 at 14:53 ET, post-market held $6.81-$6.85, on roughly 3.17 million shares. Rosenblatt reiterated a Buy rating with a $22 price target, and the company announced work with INmune Bio on quantum-optimization research for Alzheimer's drugs. The operating picture stays small-scale, with Q2 2026 revenue of $5.551 million against a $11.753 million net loss and a -211.7% net margin. The stock nonetheless remains far below its year-start level, down 38.06% year-to-date, 60.8% under the 52-week high of $17.40 and only 12.17% above the October 15 low of $6.08, trading beneath the MA20 of $7.577 and MA60 of $8.158; though Gartner has warned that more than half of quantum startups could fail by 2030.

Amid a broad quantum-sector pullback, QUBT closed up 1.25% at $6.50, tracing a dip-then-fade pattern: a pre-market low of $6.24, an intraday peak of $6.761 at 10:45 ET, a $6.49 regular-session close and $6.55 after hours. Peer pressure dominated the tape, with Rigetti and D-Wave each down about 2% and Focus Financial Network selling 882,963 shares, while Rosenblatt maintained its Buy rating and $22 price target. Fundamentals cut both ways: Q2 revenue of $5.551M alongside an $11.753M net loss that narrowed 67.78% year on year, with EPS still at -$0.0523. On price position, the stock is down 40.96% year to date, 65.57% below its 52-week high of $18.88, and trades under its MA20 of $7.692 and MA60 of $8.173, just 6.91% above the $6.08 low set on Oct 15. Though with a 0.92 price-to-book and a $1.47B market cap, the gap to its moving averages remains worth watching.

Quantum names sold off together and dragged QUBT into a high-open, low-close session, down about 6.9% to $6.365 after touching $6.98 pre-market at 04:04 ET, peaking at $6.82 at 09:36 ET and sliding to $6.35 by 13:17 ET alongside IONQ, QBTS and RGTI, following a 9.05% weekly decline. Company news was more constructive: QCi partnered with INmune Bio to apply quantum optimization and AI to Alzheimer's drug research, while Q2 2026 revenue reached $5.551M, up about 9,000% yoy, though net loss widened to $11.753M and net margin hit -211.7%. The stock is 42.23% lower YTD, 70.34% below its 52-week high of $21.44 and just 4.61% above the $6.08 low set the prior day, well under MA20 of 7.948 and MA60 of 8.215. It did rebound to $6.51 after hours, while Gartner warned over half of quantum startups may fail by 2030.

QUBT slid to a new 52-week low of $6.08 intraday, pressured by Gartner's warning that more than 50% of quantum startups could fail by 2030 and by broad weakness across quantum names, yet the stock reversed into a low-open, high-close session, ending at $6.84 versus a prior close of $6.31, up roughly 8.4%, and extending to $6.88 after hours. The turn followed a partnership with INmune Bio to apply quantum optimization and AI to Alzheimer's drug research on XPro, offsetting sector selling; turnover reached $66.6 million with a 5.07% turnover rate. Fundamentals show revenue and losses scaling together: Q2 2026 revenue was $5.551 million, up about 90x year over year, while net loss widened to $11.753 million and EPS came in at -$0.0523. The price position remains weak, down 37.87% year to date and 71.25% below the 52-week high of $23.79, still under its MA20 of $8.065 and MA60 of $8.24. Still, the rebound on heavy volume at the 52-week low points to some support near $6.